(Reuters) – Swiss drugmaker Roche’s first quarter sales rose 10%, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID-19 antigen tests.
Quarterly sales rose to 16.44 billion Swiss francs ($17.17 billion), up from 14.93 billion Swiss francs in the year-earlier period, the company said on Monday. That was slightly above a market consensus of about 16 billion francs.
Roche also confirmed its guidance for 2022.
($1 = 0.9577 Swiss francs)
(Reporting by Ludwig Burger; Editing by Miranda Murray)
